TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05216497
Drug: Ingavirin®, 90 mg capsules
DrugBank: Ingavirin (DB11944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90-180 mg/day for 7 days on top of standard therapy
Study: NCT04639271
Drug: Pyrotinib Plus And
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib::400mg/d,qd,po
Study: NCT04639271
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle
Study: NCT04639271
Drug: Abraxane
Normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abraxane 125mg/M2, qw iv
Study: NCT03177746
Drug: Dapoxetine/Tadalafil 30/20 mg film coated tablet
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During 4-weeks treatment period, patients will take one Dapoxetine/Tadalafil 30/20 mg film coated tablet 1-3 hours before sexual intercourse.~Study drug should not be used more than 1 tablet every 24 hours during the treatment.
Study: NCT05096390
Drug: Axitinib Oral Tablet [Inlyta]
Normalized name: axitinib Oral Tablet [Inlyta]
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib 5 up to 10mg twice a day
Study: NCT05096390
Drug: Pembrolizumab Injection [Keytruda]
Normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab intravenously over 30 min minutes at 200 mg every 3 weeks
Study: NCT06389617
Drug: supraclavicular block with 20mls of Ropivacaine 0.5% and Intravenous administered dexamethasone
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparing the onset of sensory, motor block, duration of motor block and analgesic duration
Study: NCT05437601
Drug: Astaxanthin Oral Capsule
Normalized name: astaxanthin Oral Capsule
DrugBank: Astaxanthin (DB06543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg oral astaxanthin daily for 8 weeks
Study: NCT06349486
Drug: vonoprazan, amoxicillin, tripotassium dicitrate bismuthate
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bismuth-amoxicillin-vonoprazan triple therapy
Study: NCT06349486
Drug: vonoprazan, amoxicillin
Normalized name: vonoprazan, amoxicillin and metronidazole
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vonoprazan-amoxicillin dual therapy
Study: NCT05303220
Drug: Branebrutinib
Normalized name: Branebrutinib
DrugBank: Branebrutinib (DB15347)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05444218
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole 400 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning after open flap debridement).
Study: NCT05444218
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 500 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning after open flap debridement).
Study: NCT04893161
Drug: Belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients with SLE will be enrolled in one year and administrated belimumab 10mg/kg intravenous infusion over 1 hour on days 0, 14, and 28, and every 28 days through week 48.
Study: NCT06118203
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide in addition to standard of care
Study: NCT04955340
Drug: [14C]-resminostat
DrugBank: Resminostat (DB12392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 single dose of 400 mg \[14C\]-resminostat
Study: NCT05753371
Drug: Metformin Hydrochloride 500 MG
Normalized name: metformin hydrochloride 500 MG
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin is an antihyperglycemic drug used in the management of type-2 diabetes. Metformin hydrochloride improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Study: NCT06063018
Drug: RC48 + Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RC48: intravenous drip, 2mg/kg, D1, repeated once every 2 weeks. Tislelizumab: intravenous drip, fixed dose 600 mg, D1, repeated once every 6 weeks.
Study: NCT06433128
Drug: Fosmanogepix solution for infusion
Normalized name: Duo Fusion
DrugBank: Fosmanogepix (DB15183)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosmanogepix solution for infusion, 20 mg/mL for intravenous administration
Study: NCT06433128
Drug: Fosmanogepix 400 mg tablets
Normalized name: Fosmanogepix
DrugBank: Fosmanogepix (DB15183)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosmanogepix 400 mg tablets for oral administration
Study: NCT06211023
Drug: SHR-1921
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1921
Study: NCT06211023
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: carboplatin AUC 4
Study: NCT06211023
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: carboplatin AUC 5
Study: NCT05741359
Drug: CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection
Normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection
Study: NCT06211023
Drug: platinum-based doublet chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: platinum-based doublet chemotherapy
Study: NCT04535024
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starts within one week upon SABR completion: 200mg, d1, q3w; Continued until disease progression, unacceptable toxicity or patient withdrawal.
Study: NCT05852769
Drug: BMS-986196
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT05852769
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05852769
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05852769
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT05852769
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05949073
Drug: impregnated gingival retraction cord - more than 10 minutes
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
DrugBank: Urethane (DB04827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the preparation of the lower first molar for full coverage restoration will be initiated - occlusal reduction, contact points breaking, and preparation with the roughest bur- then an Aluminum chloride-impregnated retraction cord will be placed and kept in the sulcus until finishing the preparation and impression recording which will take more than 10 minutes.
Study: NCT04939467
Drug: Pirfenidone 267 mg Oral Tablet
Normalized name: Pirfenidone 267 mg oral tablet
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fixed sequence use of active product, TID
Study: NCT04939467
Drug: Nintedanib 150 mg Oral Capsule
Normalized name: nintedanib 150 MG Oral Capsule
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fixed sequence use of active product, BID
Study: NCT04939467
Drug: BLD-0409 750 mg Oral Tablet
Normalized name: BLD-0409
DrugBank: Cudetaxestat (DB18203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed sequence use of active product, QD
Study: NCT00111410
Drug: Anakinra (r-metHuIL-1ra)
Normalized name: anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04825561
Drug: AD-2081
Normalized name: Stahist AD
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO, Once daily(QD), 24weeks
Study: NCT05670015
Drug: Low dosage selective alpha-2 receptor agonists topical eyedrop
Normalized name: (2S)-alpha-2-Amino-4-methylvaleric acid
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using selective alpha-2 receptor agonists eyedrop in both groups with 0.2% concentration.
Study: NCT05670015
Drug: High dosage selective alpha-2 receptor agonists topical eyedrop
Normalized name: (2S)-alpha-2-Amino-4-methylvaleric acid
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using selective alpha-2 receptor agonists eyedrop in both groups with 0.02% concentration.
Study: NCT04702360
Drug: IVA
Normalized name: Viva
DrugBank: Adenosine (DB00640)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IVA monotablet for oral administration.
Study: NCT04757662
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil is commercially available and will be purchased by the Siteman Cancer Center and distributed to participants free of charge.
Study: NCT05266196
Drug: Seclidemstat
Normalized name: Seclidemstat
DrugBank: Seclidemstat (DB17117)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment assigned as per parent protocol
Study: NCT05571345
Drug: PF614
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PF614 capsules (50 mg or 100 mg)
Study: NCT05571345
Drug: Oxycodone Hydrochloride 40 mg
Normalized name: oxycodone hydrochloride 40 MG
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral 20 mg tablets (two each)
Study: NCT04531865
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab: 375 mg/m2 intravenously on day 0 and day 7
Study: NCT04531865
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards. Dose: 20\~30mg/kg/day，BID. Total duration : 8 months.
Study: NCT04830735
Drug: Dasatinib Anhydrous
Normalized name: Dasatinib anhydrous
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT00348400
Drug: Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05559008
Drug: Azacitidine Injection
Normalized name: azacitidine Injection
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes
Study: NCT05559008
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes
Study: NCT05559008
Drug: Linperlisib
Normalized name: Linperlisib
DrugBank: Linperlisib (DB17235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azacitidine Injection，SC and Linperlisib PO will be administered in T2 subtypes
Study: NCT05559008
Drug: Tucidinostat
Normalized name: tucidinostat
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes
Study: NCT05559008
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab and Apatinib will be administered in T3.2 subtypes
Study: NCT05559008
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab and Apatinib will be administered in T3.2 subtypes
Study: NCT04789304
Drug: BI 1595043
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1595043
Study: NCT04789304
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam
Study: NCT05079451
Drug: 10-1074-LS
Normalized name: sulfacetamide
DrugBank: Sulfacetamide (DB00634)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-1074-LS will be administered by intravenous infusion (directly into the participants vein) over a period of 30 to 60 minutes. The total time needed to administer the study drug may be longer, based on factors such as participant tolerance. The participant's dose will be calculated using their most current weight on record.
Study: NCT05313009
Drug: Sotorasib and Tarloxotinib
Normalized name: sotorasib
DrugBank: Tarloxotinib (DB14944)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sotorasib 960 mg PO daily + tarloxotinib 150 mg/m2 IV weekly
Study: NCT05313009
Drug: Sotorasib and Tarloxotinib
Normalized name: sotorasib
DrugBank: Tarloxotinib (DB14944)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sotorasib 960 mg PO daily + tarloxotinib IV weekly at the combination RP2D (RP2Dc).
Study: NCT04821687
Drug: Ongentys 50mg
Normalized name: Ongentys 50mg Capsule
DrugBank: Opicapone (DB11632)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Opicapone 50mg will be added to current and stable therapy of L-DOPA/DDCI
Study: NCT05573230
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally.
Study: NCT05573230
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05418829
Drug: AT-007
Normalized name: AT-007
DrugBank: Gavorestat (DB16707)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT-007 20 mg/kg once daily
Study: NCT04831710
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab,200mg, ivd, d1
Study: NCT04831710
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Chidamide,30mg,po,biw,d1-21
Study: NCT06429904
Drug: Nimotuzumab+ NALIRIFOX
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Nimotuzumab Patients will receive Nimotuzumab 400 mg weekly or Nimotuzumab 600mg, 600mg, 400mg on Day 1, 8, 15, respectively, 28 days as a cycle, up to 6 cycles.~Other Names: h-R3~Drug: NALIRIFOX Patients will receive NALIRIFOX (liposomal irinotecan 50 mg/m2, oxaliplatin 60 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2, administered sequentially as a continuous intravenous infusion over 46 h) on days 1 and 15 of a 28-day cycle, up to 6 cycles.~Other Names: NALIRIFOX
Study: NCT05485974
Drug: HBI-2438
Normalized name: HBIG
DrugBank: Hepatitis B immune globulin (DB05276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRAS G12C Inhibitor
Study: NCT05440799
Drug: BI 1819479
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1819479
Study: NCT05232552
Drug: Anlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anlotinib was administered orally 12mg daily for 14 days concurrent with inductive chemotherapy (TP ) for 3 cycles and definitive chemoradiation for additional 2 cycles
Study: NCT03787082
Drug: Nitrates
Normalized name: Nitrates
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg/11.18 mmol, oral
Study: NCT03787082
Drug: Chlorhexidine Gluconate Mouthwash
Normalized name: chlorhexidine gluconate Mouthwash
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: chlorhexidine gluconate 0.12% (15mL) mouth rinse for 1 minute
Study: NCT04940026
Drug: amcenestrant
Normalized name: Amcenestrant
DrugBank: SAR-439459 (DB17864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet Oral
Study: NCT05442996
Drug: HLX35
Normalized name: Lanadelumab
DrugBank: Lanadelumab (DB14597)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The dose of HLX35 is set at 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. It is administered intravenously every 2 weeks on day 1 of each cycle.
Study: NCT05442996
Drug: HLX10
Normalized name: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.-chain, dimer
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of HLX10 is fixed at 200 mg. It is administered intravenously once every 2 weeks on day 1 of each cycle.
Study: NCT04988867
Drug: Trofinetide
Normalized name: Trofinetide
DrugBank: Trofinetide (DB06045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trofinetide solution of 10-30 mL based on subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
Study: NCT05956639
Drug: 6-month course of antiandrogen drugs
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-month course of Rezvilutamide and ADT + chemotherapy
Study: NCT05956639
Drug: Long-term course of antiandrogen drugs
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term course of Rezvilutamide and ADT + chemotherapy
Study: NCT00002323
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002323
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05567354
Drug: PF614
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PF614 100 mg capsules
Study: NCT05567354
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone HCl IR 40mg
Study: NCT05229042
Drug: Ricolinostat
Normalized name: Ricolinostat
DrugBank: Ricolinostat (DB12376)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT06258226
Drug: Conventional dosage reduction
Normalized name: reductic acid
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The doctor will guide patients to adjust medication dosage once a week in the outpatient clinic. When patients experience withdrawal reactions such as worsening insomnia or anxiety symptoms due to drug reduction, they will be returned to the oral dose before the current reduction, and the dosage will be reduced again after evaluation in the next reduction cycle. The treatment for 4 weeks is one course and 1 course of treatment is required totally.
Study: NCT04679480
Drug: Cemiplimab Injection [Libtayo]
Normalized name: cemiplimab Injection [Libtayo]
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Investigational product: a combination of an anti-PD1 antibody (Cemiplimab) and a HHI (Sonidegib).~Cemiplimab will be supplied as a liquid in a sterile, single-use 10 ml vial. Each vial will contain a volume of 7ml at a concentration of 50mg/ml. Cemiplimab will be prepared for infusion (as described in SmPC (Fachinformation Swissmedic) Libtayo, see Appendix) at the trial site and administered as a flat 350mg dose in 100ml NaCl 0.9% as an IV infusion over approximately 30 minutes (±10 minutes) in an outpatient setting. Each patient's dose will be administered as a flat 350mg dose in every 3 weeks, starting from week 2 of the trial.~The Hedgehog Inhibitor used for the trial will be Sonidegib. Sonidegib is a white 200mg capsule, orally administered once daily. Sonidegib will be administered in a 2 week cycle every 4 weeks (pulsed therapy: 2 weeks on, 2 weeks off), starting from week 0 of the trial.
Study: NCT05949294
Drug: ARO-SOD1 Injection
Normalized name: ARO-APOC3
DrugBank: ARO-APOC3 (DB17625)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single doses of ARO-SOD1 Injection by IT infusion
Study: NCT04483414
Drug: 68Ga PSMA-11 injection
Normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 68Ga PSMA-11
Study: NCT00703235
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT05449899
Drug: Granulocyte Colony-Stimulating Factor(G-CSF)
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
Study: NCT05449899
Drug: Decitabine (DAC)
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine was administered at 20mg/m2/day on days -14 to -10.
Study: NCT05449899
Drug: Busulfan (BU)
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group, and it was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group .
Study: NCT05449899
Drug: Fludarabine (FLU)
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
Study: NCT06057194
Drug: Letermovir 240 mg Oral Tablet
Normalized name: Letermovir 240 mg oral tablet
DrugBank: Letermovir (DB12070)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment will commence as soon as subjects can receive oral medication, with a maximum timeframe of 28 days after transplantation. If patients cannot receive oral medication after transplantation, initial prophylaxis with ganciclovir per clinical practice will be allowed. Medication will be discontinued 12 months after treatment initiation.
Study: NCT06207331
Drug: Dexmedetomidine 0.5 μg/kg
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants inhale the atomized 0.5 μg/kg dexmedetomidine in 2 ml of 0.9% saline.
Study: NCT06207331
Drug: Dexmedetomidine 1 μg/kg
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants inhale the atomized 1 μg/kg dexmedetomidine in 2 ml of 0.9% saline.
Study: NCT06207331
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants inhale atomized 2 ml 0.9% saline.